2025-09-25 - Analysis Report
Okay, here's an analysis of Merck & Co Inc (MRK) based on the provided data, formatted for a concise English report with key figures highlighted first:

## Merck & Co Inc (MRK) Stock Analysis

**Company Overview:** Merck & Co Inc is a global pharmaceutical company that develops and markets a wide range of healthcare products.

### 1. Performance vs. S&P 500 (VOO)

*   **MRK Cumulative Return:** -16.38%
*   **VOO Cumulative Return:** 69.58%
*   **Divergence (MRK - VOO):**
    *   **Current:** -117.8
    *   **Max:** 23.1
    *   **Min:** -117.8
    *   **Relative Divergence:** 0.0

**Analysis:** MRK has significantly underperformed the S&P 500 (VOO) over the observed period, resulting in a substantial negative divergence. The relative divergence of 0.0 indicates that the current underperformance is at the lowest end of its historical range relative to VOO.

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
| ---------- | ------- | ------- | ------- | ------ | ------ |
| 2015-2017  | -3.0%  | 78.3%  | -28.0% | 0.1   | 134.1  |
| 2016-2018  | 31.0%  | 99.0%  | 13.0%  | 0.1   | 182.1  |
| 2017-2019  | 41.0%  | 99.0%  | 15.0%  | 0.3   | 216.7  |
| 2018-2020  | 25.0%  | 99.0%  | 13.0%  | 0.2   | 194.9  |
| 2019-2021  | 5.0%   | 99.0%  | -24.0% | 0.5   | 191.4  |
| 2020-2022  | -5.0%  | 99.8%  | 0.0%   | 0.5   | 277.1  |
| 2021-2023  | 6.0%   | 99.8%  | -5.0%  | 0.3   | 272.3  |
| 2022-2024  | -21.0% | 99.8%  | -45.0% | 0.3   | 248.4  |
| 2023-2025  | -43.0% | 73.1%  | -82.0% | -0.1  | 199.3  |

**Analysis:**

*   **CAGR:** Variable, with recent years showing negative growth.
*   **MDD:** Consistently high Maximum Drawdown, indicating significant volatility.
*   **Alpha:** Predominantly negative or low, suggesting underperformance relative to its risk-adjusted benchmark.
*   **Beta:** Low, indicating lower sensitivity to market movements.  The recent negative beta suggests a potential inverse correlation in the latest period.
*   **Market Cap:** Large-cap company with fluctuations in market capitalization.

### 2. Recent Stock Price Movements

*   **Current Price:** 79.79
*   **Last Market Data:** price: 79.785, previousClose: 79.96, change: -0.22
*   **5-day Moving Average:** 80.874
*   **20-day Moving Average:** 83.0572
*   **60-day Moving Average:** 82.5199

**Analysis:** The current price is below all three moving averages, suggesting a short-term downward trend. The slight negative change in the last market data reinforces this trend.

### 3. Technical Indicators & Outlook

*   **Market Risk Indicator (MRI):** 0.434 (Medium Risk)
*   **RSI:** 28.07 (Oversold)
*   **PPO:** -0.6057
*   **Hybrid Signal:** cash_72%_Sell 11.6% of holdings (49 shares - Risky - MRI:0.42) (Cash Ratio: 72% on 2025-09-18)
*   **Recent Relative Divergence Change (20-day):** 0.0 (Short-term decline)
*   **Expected Return (%):** -1419.0 (Significant underperformance vs. S&P 500 in the long term)

**Analysis:**

*   The RSI indicates that the stock is currently oversold, which could suggest a potential for a short-term rebound.
*   The negative PPO reinforces the downward momentum.
*   The Hybrid Signal suggests reducing holdings due to risk.
*   The extremely negative expected return indicates a very pessimistic outlook relative to the S&P 500. The large negative value should be viewed cautiously, as it could be influenced by specific model assumptions and past performance. The price decrease of -0.22 isn't significant enough to be considered a major event.

### 4. Recent News & Significant Events

*   **Gilead Sciences Surges 26.5% YTD:** A competitor's positive performance could indirectly affect investor sentiment towards the pharmaceutical industry.
*   **Executive Appointment at TruTechnologies:** This is unlikely to have a direct impact on Merck's stock.
*   **Dividend Stock Articles:** These articles may highlight dividend-paying stocks in general, but whether they include MRK would determine direct relevance.
*   **Siemens' AI and Robotics Push:** The general trend towards technology innovation in the medical field is shown with this article.
*    **Eli Lilly's boss calls UK the 'worst' European country for drug prices** This article about another pharmaceutical company highlights a general issue in the industry.

**Analysis:** The news items are a mix of industry trends and competitor news. The Eli Lilly comment on drug prices in the UK is a negative sentiment in the industry.

### 4-2) Analyst Opinions

*   **Consensus:** Buy (Mean: 2.00)
*   **Opinions:** 25
*   **Target Price (avg/high/low):** 101.60 / 141.00 / 82.00
*   **Recent Rating Changes:** No changes.

**Analysis:** Despite the stock's recent poor performance, analysts maintain a "Buy" consensus with a significant upside potential based on the average target price. The range of target prices is quite wide, suggesting some uncertainty among analysts.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue      |
| ---------- | ---- | ------------ |
| 2025-08-05 | 1.76 | 15.81 B$     |
| 2025-05-02 | 2.01 | 15.53 B$     |
| 2024-11-06 | 1.25 | 16.66 B$     |
| 2024-08-05 | 2.15 | 16.11 B$     |
| 2025-08-05 | 2.15 | 16.11 B$     |

**Analysis:** Earnings per share (EPS) and revenue have fluctuated. Recent EPS has been lower, which may be contributing to the stock's underperformance.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | ------------- |
| 2025-06-30 | $15.81B   | 77.50%       |
| 2025-03-31 | $15.53B   | 77.98%       |
| 2024-12-31 | $15.62B   | 75.50%       |
| 2024-09-30 | $16.66B   | 75.51%       |
| 2024-06-30 | $16.11B   | 76.76%       |

**Capital and Profitability:**

| Quarter    | Equity    | ROE   |
| ---------- | --------- | ----- |
| 2025-06-30 | $48.99B   | 9.04% |
| 2025-03-31 | $48.34B   | 10.51% |
| 2024-12-31 | $46.31B   | 8.08% |
| 2024-09-30 | $44.50B   | 7.09% |
| 2024-06-30 | $43.58B   | 12.52% |

**Analysis:** Revenue has been relatively stable. Profit margins are high. Return on Equity (ROE) has fluctuated but generally remains positive.

### 7. Overall Assessment

MRK is currently underperforming the S&P 500 and exhibiting a short-term downward trend. Technical indicators suggest it is oversold, which could lead to a potential bounce. However, negative alpha and an extremely pessimistic expected return (compared to the S&P 500) raise concerns. Analyst consensus remains positive, but the wide range of target prices indicates uncertainty. While revenue and profit margins are strong, recent EPS has been lower.
